MTAC MedTech Acquisition Corporation

1	NAMES OF REPORTING PERSONS
	Magnetar Financial LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)	☐
				(b)	☐
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	OO
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER
			0
		8	SHARED VOTING POWER
			700,005
		9	SOLE DISPOSITIVE POWER
			0
		10	SHARED DISPOSITIVE POWER
			700,005
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	700,005
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	61.1% (1)
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	IA; OO

 

1	NAMES OF REPORTING PERSONS
	Magnetar Capital Partners LP
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)	☐
				(b)	☐
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	OO
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER
			0
		8	SHARED VOTING POWER
			700,005
		9	SOLE DISPOSITIVE POWER
			0
		10	SHARED DISPOSITIVE POWER
			700,005
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	700,005
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	61.1% (1)
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	HC; OO

 

1	NAMES OF REPORTING PERSONS
	Supernova Management LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)	☐
				(b)	☐
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	OO
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER
			0
		8	SHARED VOTING POWER
			700,005
		9	SOLE DISPOSITIVE POWER
			0
		10	SHARED DISPOSITIVE POWER
			700,005
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	700,005
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	61.1% (1)
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	HC; OO

 

1	NAMES OF REPORTING PERSONS
	David J. Snyderman
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)	☐
				(b)	☐
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	OO
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION
	United States of America
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER
			0
		8	SHARED VOTING POWER
			700,005
		9	SOLE DISPOSITIVE POWER
			0
		10	SHARED DISPOSITIVE POWER
			700,005
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	700,005
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	61.1% (1)
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	HC; IN

 

SCHEDULE 13D

Explanatory Note: This Amendment No. 2 (“Amendment No. 2”) amends and supplements the original Schedule 13D filed on December 22, 2022 (the “Original Schedule 13D”), as amended and supplemented by Amendment No. 1 filed on February 9, 2023 (collectively, the “Schedule 13D”) relating to shares of Class A common stock, par value $0.0001 per share (the “Shares”), of MedTech Acquisition Corp, a company incorporated in Delaware (the “Issuer”). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.

 

Item 4 of the Schedule 13D is hereby amended and supplemented as follows:

In connection with the special meeting of the stockholders of the Issuer on June 12, 2023, the Reporting Persons elected to redeem, and the Issuer accepted for redemption, an aggregate of 445,828 Shares at a redemption price of approximately $10.4861 per Share, including the redemption of:

(i) 67,992 Shares held for the benefit of a separately managed account,

(ii) 107,904 Shares held for the benefit of Constellation Fund II,

(iii) 27,891 Shares held for the benefit of a separately managed account,

(iv) 21,887 Shares held for the benefit of Healthcare Master Fund,

(v) 16,032 Shares held for the benefit of Lake Credit Fund,

(vi) 85,137 Shares held for the benefit of SC Fund,

(vii) 33,227 Shares held for the benefit of Structured Credit Fund,

(viii) 38,079 Shares held for the benefit of a separately managed account,

(ix) 42,567 Shares held for the benefit of Purpose Fund, and

(x) 5,112 Shares held for the benefit of Purpose Fund – T.

Item 5(a)-(c) of the Schedule 13D is hereby amended and supplemented as follows:

(i) 391,047 Shares held for the benefit of Constellation Master Fund,

(ii) 3 Shares held for the benefit of a separately managed account,

(iii) 1 Share held for the benefit of Healthcare Master Fund,

(iv) 52,275 Shares held for the benefit of Lake Credit Fund,

(v) 108,343 Shares held for the benefit of Structured Credit Fund,

(vi) 131,667 Shares held for the benefit of Xing He Master Fund,

(vii) 1 Share held for the benefit of a separately managed account,

(viii) 16,668 Shares held for the benefit of Purpose Fund – T.

(c) The response to Item 4 of this Amendment No. 2 is incorporated herein by reference.  Except as otherwise described in this Amendment No. 2, the Reporting Persons had no transactions in the Shares during the 60 days preceding the date of filing of this Amendment No. 2.

Item 6 of the Schedule 13D is hereby amended and supplemented as follows:

On March 4, 2023, the Issuer, TriSalus and the Investor amended the Term Sheet (the “Amendment No. 1 to Term Sheet”) to increase the cap for the reimbursement of the Investor’s expenses incurred in connection with the transactions contemplated in the Term Sheet from $300,000 to $600,000. The foregoing description of the Amendment No. 1 to Term Sheet does not purport to be complete and is qualified in its entirety by the terms and conditions of the Amendment No. 1 to Term Sheet, which is included as Exhibit 4 to this Amendment No. 2 and is incorporated herein by reference.

Except as otherwise described in the Schedule 13D, as amended by this Amendment No. 2, no contracts, arrangements, understandings or similar relationships exist with respect to the securities of the Issuer among or between the Reporting Persons or any other person or entity.

ITEM 7.

MATERIAL TO BE FILED AS EXHIBITS

Item 7 of the Schedule 13D is hereby amended and restated as follows:

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.